AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03935334 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biosimilar eptacog alfa, activated (AryoSeven)
Description: A single dose of eptacog alfa biosimilar (AryoSeven) 90 μg/kg or 270 μg/kg. Then, in an open follow up phase of 12 months, for every bleeding episode patients will receive eptacog alfa biosimilar, on demand, for one of more days until resolution of bleeding, based on the Investigator's decision - or - prophylaxis with eptacog alfa biosimilar, with dose, frequency, and duration of treatment based on the Investigator's decision. The modality of treatment (on demand or prophylaxis) will be decided by the Investigator.
Study NCT03935334 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Eptacog alfa, activated (Novoseven)
Description: A single dose of eptacog alfa (Novoseven) 90 μg/kg or 270 μg/kg. Then, in an open follow up phase of 12 months, for every bleeding episode patients will receive eptacog alfa biosimilar, on demand, for one of more days until resolution of bleeding, based on the Investigator's decision - or - prophylaxis with eptacog alfa biosimilar, with dose, frequency, and duration of treatment based on the Investigator's decision. The modality of treatment (on demand or prophylaxis) will be decided by the Investigator.
Study NCT03706976 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tissue Oxygenation Monitoring
Description: The NIRS sensor will be applied to the abdomen of the study population. To ensure good skin contact the sensor will be placed underneath the diaper. If that should not provide enough measurement stability, additional fixation will be given by employing aforementioned flexible bandage routinely employed in neonatal care. Once good skin contact is ensured, the sensor will measure aStO2 for up to seventy-two hours. The presence of this sensor will not disturb daily clinical activities or medical treatment in any way. Should good skin contact be endangered by movements, clinical interactions or such, the sensor will be removed and re-attached to the infants' abdomen as a consequence.
Study NCT02949141 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung Ultrasound
Description: All patients will receive lung ultrasound, chest x-ray and computed tomography
Study NCT02949141 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chest X-ray
Description: All patients will receive chest x-ray as per usual care for evaluation for pneumonia
Study NCT02949141 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chest Computed Tomography (CT)
Description: All enrolled patients will receive a CT scan as the gold standard for diagnosing pneumonia
Study NCT00061750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICL670
Study NCT00061750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: deferoxamine
Study NCT03747809 — intervention group
Intervention type: DEVICE
Intervention: CIEDs Remote Monitoring System
Description: Cardiac device remote monitoring system
Study NCT03434028 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Early Vasopressors
Description: Norepinephrine will be used as preferred vasopressor and titrated to achieve mean arterial pressure (MAP) between 65 mmHg and 75 mmHg. Rescue fluids may be administered as 500ml boluses if predefined rescue criteria are met.
Study NCT03434028 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Early Fluids
Description: Additional 2 liter intravenous fluid infusion upon enrollment (may forego second liter if MAP/SBP and heart rate are normalized and clinical assessment if patient is fluid replete after the first liter). Administer 500ml fluid boluses for fluid triggers until 5 liters administered or development of clinical signs of acute volume overload develop. Rescue vasopressors may be administered after 5 liters of fluid, for development of acute volume overload, or if other predefined rescue criteria are met. Any type of isotonic crystalloid (normal saline, ringers lactate, balanced solution such as plasmalyte) is permitted.
Study NCT01458847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cis-UCA solution
Description: Cohort I: 2% cis-UCA solution (50 ml); min 3, max 12 patients
Study NCT01458847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cis-UCA solution
Description: Cohort II: 4% cis-UCA solution (50 ml); min 0, max 12 patients
Study NCT01458847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cis-UCA solution
Description: Cohort III: 6% cis-UCA solution (50 ml); min 0, max 12 patients
Study NCT02759926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denatonium benzoate
Study NCT02759926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quinine hydrochloride
Study NCT02759926 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tap water
Study NCT04038697 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ischemic Conditioning
Description: Ischemic conditioning is a well-defined, non-invasive procedure which consists of inflating a blood pressure cuff around a limb (in our study, the paretic leg), inflating the cuff to 225 mmHg to occlude blood flow to the limb for 5 minutes, releasing the cuff for 5 minutes, and repeating 5 times. In our study, participants assigned to the IC Only and IC + Treadmill Training groups will undergo twelve sessions of ischemic conditioning over a four-week period.
Study NCT04038697 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ischemic Conditioning
Description: Ischemic conditioning is a well-defined, non-invasive procedure which consists of inflating a blood pressure cuff around a limb (in our study, the paretic leg), inflating the cuff to 225 mmHg to occlude blood flow to the limb for 5 minutes, releasing the cuff for 5 minutes, and repeating 5 times. In our study, participants assigned to the IC Only and IC + Treadmill Training groups will undergo twelve sessions of ischemic conditioning over a four-week period.
Study NCT04038697 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ischemic Conditioning Sham
Description: Ischemic conditioning sham consists of the same setup as ischemic conditioning, which consists of inflating a blood pressure cuff around a limb (in our study, the paretic leg), inflating the cuff to 10 mmHg for 5 minutes, releasing the cuff for 5 minutes, and repeating 5 times. 10 mmHg is a sufficient inflation pressure for study participants to perceive some cuff tightness, but is not high enough to occlude blood flow. In our study, participants assigned to the IC Sham + Treadmill Training groups will undergo twelve sessions of ischemic conditioning sham over a four-week period.
Study NCT04038697 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill Training
Description: Participants will perform 3 treadmill training sessions/week for a 4 week period (12 sessions total). Treadmill training will immediately follow IC or IC Sham. Personnel performing the treadmill training will be blinded to the IC treatment group. Subjects will walk on a treadmill for six, 5-minute intervals. Walking speed will be continuously adjusted to maintain heart rate between 50% and 60% of age-adjusted heart rate reserve to minimize the confounder of intensity. If individuals cannot walk at 80% of their overground self-selected walking speed, for 5 minutes, they will be assisted into a body weight support harness. Body weight support will be adjusted (up to 50%) such that individuals can walk at 80% of their over ground walking speed for five minutes and adjusted accordingly throughout the session. Participants assigned to the Treadmill + IC and Treadmill + IC Sham groups will receive Treadmill Training.
Study NCT04038697 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treadmill Training
Description: Participants will perform 3 treadmill training sessions/week for a 4 week period (12 sessions total). Treadmill training will immediately follow IC or IC Sham. Personnel performing the treadmill training will be blinded to the IC treatment group. Subjects will walk on a treadmill for six, 5-minute intervals. Walking speed will be continuously adjusted to maintain heart rate between 50% and 60% of age-adjusted heart rate reserve to minimize the confounder of intensity. If individuals cannot walk at 80% of their overground self-selected walking speed, for 5 minutes, they will be assisted into a body weight support harness. Body weight support will be adjusted (up to 50%) such that individuals can walk at 80% of their over ground walking speed for five minutes and adjusted accordingly throughout the session. Participants assigned to the Treadmill + IC and Treadmill + IC Sham groups will receive Treadmill Training.
Study NCT04038697 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Treadmill Training
Description: Participants will perform 3 treadmill training sessions/week for a 4 week period (12 sessions total). Treadmill training will immediately follow IC or IC Sham. Personnel performing the treadmill training will be blinded to the IC treatment group. Subjects will walk on a treadmill for six, 5-minute intervals. Walking speed will be continuously adjusted to maintain heart rate between 50% and 60% of age-adjusted heart rate reserve to minimize the confounder of intensity. If individuals cannot walk at 80% of their overground self-selected walking speed, for 5 minutes, they will be assisted into a body weight support harness. Body weight support will be adjusted (up to 50%) such that individuals can walk at 80% of their over ground walking speed for five minutes and adjusted accordingly throughout the session. Participants assigned to the Treadmill + IC and Treadmill + IC Sham groups will receive Treadmill Training.
Study NCT00940862 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Injection of adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 15 weeks)
Study NCT00940862 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UVB Phototherapy
Description: This intervention can be applied alone or in combination with topical treatment. It will be performed between Day 0 and Day 112. The investigator is free to introduce or modify the topical and/or UVB regimens at any time after screening.
Study NCT00940862 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Topical treatment
Description: This intervention can be applied alone or in combination with UVB phototherapy. It will be performed between Day 0 and Day 112. The investigator is free to introduce or modify the topical and/or UVB regimens at any time after screening. The investigator will prescribe to patients randomized in this arm a select topical product from the list:~Calcipotriol, Calcipotriene, Dovonex, Tazorac, Tazarotene Anthralin, Corticosteroids.
Study NCT00585078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study NCT00585078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study NCT00985270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Study NCT00985270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03391856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl-L-cysteine (NAC)
Description: NAC treatment for PT: 400mg p.o tid from day 60 to 90 post transplant
Study NCT03391856 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: supportive therapy
Description: prophylactic platelet transfusion was given when platelet count \<20000/ul
Study NCT02438371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Study NCT02438371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Study NCT00509405 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: potassium citrate
Description: 6 times 10 mEq per day, oral for 24 months
Study NCT02689947 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Silk
Study NCT02781311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setipiprant
Description: Setipiprant tablets, orally, BID for 24 weeks.
Study NCT02781311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, orally, BID for 24 weeks.
Study NCT02781311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finasteride
Description: Finasteride tablet, orally, once daily for 24 weeks.
Study NCT02788071 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FMT capsules
Description: 25 capsules per day for 12 days
Study NCT02788071 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: FMT placebo
Description: 25 capsules per day for 12 days
Study NCT01066715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XOMA 052
Description: Sterile solution subcutaneously administered monthly for 6 months
Study NCT01066715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile solution subcutaneously administered monthly for 6 months
Study NCT03764995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard bowel management
Description: Lifestyle advices such as increasing fluid and fibre intake, improving physical activity level, and taking the ideal posture for defecation (squatting position) with a two-pages document.
Study NCT03764995 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard bowel management
Description: Lifestyle advices such as increasing fluid and fibre intake, improving physical activity level, and taking the ideal posture for defecation (squatting position) with a two-pages document.
Study NCT03764995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal massage
Description: Abdominal massage will be performed three days a week for four weeks. Each session will last around 15-20 minutes.
Study NCT03764995 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ultrasound
Description: Placebo ultrasound (US) will be applied to the abdominal region for four weeks, 2 days of the week and 15 minutes per day.
Study NCT00832364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acitretin (also called U0279)
Description: Capsules containing 25 mg U0279 taken once a day.
Study NCT00832364 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT00832364 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Injectable Biologic
Study NCT00832364 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Etanercept
Description: Injectable Biologic
Study NCT04438122 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cabernet Sauvignon
Description: Cabernet Sauvignon is a red wine from a greek company which contains 13.5% alcohol vol.
Study NCT04438122 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tsipouro
Description: Tsipouro is a greek spirit which contains 38% alcohol vol
Study NCT01157351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paliperidone
Description: flexible dosing as prescribed by the study doctor for 15 months
Study NCT01157351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: flexible dosing as prescribed by the study doctor for 15 months
Study NCT01157351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: haloperidole
Description: flexible dosing as prescribed by the study doctor for 15 months
Study NCT01157351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: perphenazine
Description: flexible dosing as prescribed by the study doctor for 15 months
Study NCT01157351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aripiprazole
Description: flexible dosing as prescribed by the study doctor for 15 months
Study NCT01157351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quetiapine
Description: flexible dosing as prescribed by the study doctor for 15 months
Study NCT01157351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paliperidone palmitate
Description: 78, 117, 156, or 234 mg monthly injection for 15 months
Study NCT01157351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: flexible dosing as prescribed by the study doctor for 15 months
Study NCT00890539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methacholine challenge
Description: Clinical and research test used in asthma
Study NCT00890539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methacholine challenge
Description: Clinical and research test used in asthma
Study NCT03527641 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CookingMatters
Description: Nutrition education and hands-on cooking lessons for the whole family
Study NCT03527641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CookingMatters
Description: Nutrition education and hands-on cooking lessons for the whole family
Study NCT03527641 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Education
Description: Parenting, physical activity and nutrition education, and family health education for parents
Study NCT03527641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Education
Description: Parenting, physical activity and nutrition education, and family health education for parents
Study NCT03527641 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: Physical fitness activities for teens
Study NCT03527641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Physical fitness activities for teens
Study NCT03527641 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Health knowledge curriculum for adolescents
Study NCT03527641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction
Description: Adolescent mindfulness curriculum
Study NCT03527641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Mindfulness Intervention
Description: Parent-based education and experiential learning of mindfulness-based tools
Study NCT01988298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen 400 mg each 8 hours
Study NCT01988298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Control group
Study NCT00814411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group family planning counseling
Description: group family planning counseling for gynecological patients with unmet need
Study NCT00814411 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual family planning counseling
Description: Individual family planning counseling with gynecological patients - the current standard of care
Study NCT02306447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rPMS and rTMS
Description: rPMS Stimulation of the neck muscles in five medial-lateral movements starting from the neck: left and right trapezius and deltoid muscle, trapezius and lattissimus dorsi muslce, and over the backbone. 20 stimuli per movement with 2s inter-train interval; four repetitions for each of the five movements; the first 20 trains with a frequency of 5Hz, the second 20 trains at 20Hz; stimulation at individual comfortable level (20-30% stimulator output); round coil.~rTMS 20Hz stimulation with 2000 stimuli over the left dorso-lateral prefrontal cortex at 110% motor threshold; followed by 1Hz stimulation with 2000 stimuli over the left temporo-parietal cortex; stimulation intensity 110% motor threshold; butterfly coil.~For stimulation we use MagPro X100 (Medtronic, Denmark).
Study NCT01050361 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transthoracic Echocardiogram (TTE)/Transesophageal Echocardiogram (TEE)
Description: Duration lasts the entire operation.
Study NCT04388696 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sisterhood 2.0
Description: The Sisterhood 2.0 curriculum was adapted from Program M, created in 2006 by Promundo to address health and empowerment of young women aged 15-24. The curriculum engages young women in questioning rigid and non-equitable stereotypes about masculinity and femininity and how they affect both women's and men's health and well-being.
Study NCT04388696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sisterhood 2.0
Description: The Sisterhood 2.0 curriculum was adapted from Program M, created in 2006 by Promundo to address health and empowerment of young women aged 15-24. The curriculum engages young women in questioning rigid and non-equitable stereotypes about masculinity and femininity and how they affect both women's and men's health and well-being.
Study NCT01672398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitoring plus self-management support
Description: Patients in the intervention group receive automated telephone calls that ask about their health and self-care along with tailored health-related feedback. The patient's CarePartner receives health update reports about the patient and how they can help via e-mail. Urgent health problems are reported to the patient's health care team via fax or e-mail.
Study NCT00523068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine
Study NCT00523068 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tension free vaginal tape
Study NCT00207402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosiglitazone
Description: Infergen 15mcg/ d Avandia qd Ribavirin bid
Study NCT03853252 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Skin biopsy
Description: Skin biopsy on a location preliminarily anesthetized Disinfection protocol Combined required blood tests (HIV, Hepatitis B)